Strengths

Cash conversion cycle of 6.3 days suggests relatively efficient working-capital management versus many medtech peers, supporting liquidity and operational flexibility.

Current ratio of 1.88 and quick ratio of 1.69 indicate near-term balance-sheet coverage above distressed peers, reducing refinancing pressure in a capital-intensive industry.

Negative net debt to EBITDA reflects EBITDA losses rather than leverage burden, which is structurally less constraining than highly levered peers with positive earnings.

ROIC of -21.1% is weak, but the absence of severe liquidity stress partially offsets it versus peers that combine losses with tighter short-term funding profiles.

Weaknesses

ROIC of -21.1% shows capital is not earning its cost, leaving STIM structurally behind profitable peers that convert invested capital into durable returns.

Debt-to-equity of 4.85 signals a leveraged capital structure, which is materially less resilient than peers with lower balance-sheet dependence and stronger equity cushions.

Negative EBITDA implied by net debt to EBITDA limits internal funding capacity, making STIM weaker than peers that self-finance growth through operating cash generation.

Liquidity ratios are adequate but not exceptional, so they do not offset the company’s persistent profitability gap versus stronger medtech competitors.

Opportunities

If operating losses narrow, STIM can translate its relatively efficient working-capital profile into better cash generation than peers with slower conversion cycles.

Balance-sheet liquidity provides room to support commercialization or product adoption initiatives, whereas weaker peers may face tighter funding constraints.

Improving capital efficiency would have outsized impact because current returns are deeply negative, so even modest margin progress could narrow the peer gap.

A lower cash conversion cycle than many peers can amplify the benefit of any revenue recovery by releasing cash faster into the business.

Threats

Persistent negative returns threaten long-term competitiveness because peers with positive ROIC can reinvest more aggressively and compound market share over time.

High debt-to-equity increases vulnerability to adverse operating trends, leaving STIM less flexible than peers if financing conditions tighten.

If EBITDA remains negative, leverage metrics will stay structurally pressured, which can constrain strategic options relative to better-capitalized competitors.

Weak profitability versus peers raises the risk that incremental growth destroys value, especially in a sector where scale and reimbursement execution matter.

Overall Score

STIM’s structural positioning is weak versus peers because negative returns and leveraged capital structure outweigh its relatively solid near-term liquidity and working-capital efficiency.